TITLE

Ceftriaxone: An Update of its Use in the Management of Community-Acquired and Nosocomial Infections

AUTHOR(S)
Lamb, H.M.; Ormrod, D.; Scott, L.J.; Figgitt, D.P.
PUB. DATE
April 2002
SOURCE
Drugs;2002, Vol. 62 Issue 7, p1041
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Ceftriaxone is a parenteral third-generation cephalosporin with a long elimination half-life which permits once-daily administration. It has good activity against Streptococcus pneumoniae, methicillin-susceptible staphylococci, Haemophilus influenzae, Moraxella catarrhalis and Neisseria spp. Although active against Enterobacteriaceae, the recent spread of derepressed mutants which hyperproduce chromosomal β-lactamases and extended-spectrum β-lactamases has diminished the activity of all third-generation cephalosporins against these pathogens necessitating careful attention to sensitivity studies. Extensive data from randomised clinical trials confirm the efficacy of ceftriaxone in serious and difficult-to-treat community-acquired infections including meningitis, pneumonia and nonresponsive acute otitis media. Ceftriaxone also has efficacy in other community-acquired infections including uncomplicated gonorrhoea, acute pyelonephritis and various infections in children. In the nosocomial setting, extensive data also confirm the efficacy of ceftriaxone with or without an aminoglycoside in serious Gram-negative infections, pneumonia, spontaneous bacterial peritonitis and as surgical prophylaxis. Outpatient use of ceftriaxone, either as part of a step-down regimen or parenterally, is a distinguishing feature of the data gathered on the agent over the last decade. The review focuses on new applications of the drug and its use in infections in which the causative pathogens or their resistance patterns have changed over the past decade. Ceftriaxone has a good tolerability profile, the most common events being diarrhoea, nausea, vomiting, candidiasis and rash. Ceftriaxone may cause reversible biliary pseudolithiasis, notably at higher dosages of the drug (≥2 g/day); however, the incidence of true lithiasis is <0.1%. Injection site discomfort or phlebitis can occur after intramuscular or intravenous administration. Conclusions: As a result of its strong activity against S. pneumoniae, ceftriaxone holds an important place, either alone or as part of a combination regimen, in the treatment of invasive pneumococcal infections, including those with reduced β-lactam susceptibility. Its once-daily administration schedule allows simplification of otherwise complex regimens in a hospital setting and has also contributed to its popularity as a parenteral agent in an ambulatory setting. These properties, together with a well characterised tolerability profile, mean that ceftriaxone is likely to retain its place as an important third-generation cephalosporin in the treatment of serious community-acquired and nosocomial infections.
ACCESSION #
6604886

 

Related Articles

  • Laboratory and Clinical Evaluation of a New Antibiotic--Cephalothin. Turck, Marvin; Anderson, Kenneth N.; Smith, Ronald H.; Wallace, James E.; Petersdorf, Robert G. // Annals of Internal Medicine;Aug65, Vol. 63 Issue 2, p199 

    Describes the use of antibiotic cephalothin for the treatment of various infections. Tube dilution sensitivity tests of gram-negative pathogens with cephalothin; Comparison of cephalothin with other antibiotics; Effect of inoculum size on sensitivity of gram-negative pathogens to cephalothin.

  • Cefditoren Pivoxil: A Viewpoint by Joseph L. Kuti. Kuti, J.L. // Drugs;2002, Vol. 62 Issue 2, p337 

    Examines the effectiveness of cefditoren pivoxil in the treatment of upper respiratory tract infections. Duration of time-dependent bactericidal activity; Importance to community-acquired pneumonia; Advantage of the cephalosporin.

  • Cephalosporins: The fourth generation. Cerrato, Paul L. // RN;Nov99, Vol. 62 Issue 11, p94 

    Reports on the United States Food & Drug Administration's approval of cephalosporins for the treatment of urinary tract complications, pneumonia, uncomplicated soft tissue and skin infections.

  • Anti-MRSA Cephems: An Update. Springer, Dane M. // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p269 

    A review of recent developments in the field of anti-MRSA cephems is presented. The R.W. Johnson / Microcide collaboration seems to be the most advanced effort to date, but many other companies are continuing their efforts to develop a cephalosporin for use against serious Gram-positive...

  • Ceftriaxone Alone or in Combination with Antibiotics in the Management of Infection in Cancer Patients: A Review of 41 Clinical Trials Involving 7350 Patient-Episodes. Venditti, M.; Martino, P.; Viscoli, C.; Klastersky, J. // Clinical Drug Investigation;1999, Vol. 17 Issue 3, p195 

    Empirical therapy with a broad-spectrum β-lactam and an aminoglycoside is the cornerstone of the management of patients with granulocytopenia and fever. These regimens are able to considerably lower mortality associated with serious infections; however, the optimal management of fever in...

  • Claforan.  // Royal Society of Medicine: Medicines;2002, p157 

    The article presents information on Claforan, a proprietary, prescription-only preparation of the antibacterial and antibiotic cefotaxime. It can be used to treat a range of infections, and is available in a form for injection.

  • Newer Cephalosporins are Only Marginal Advancements Over Existing Compounds. Cazzola, Mario; Blasi, Francesco; Matera, Maria Gabriella // Current Medicinal Chemistry - Anti-Infective Agents;Jul2002, Vol. 1 Issue 3, p281 

    Multidrug-resistant Gram-positive bacteria have become an increasing problem for the management of serious infections. Also extended-spectrum �-lactamase producing Gram-negative bacilli is a growing concern. A number of novel parenteral or oral cephalosporins have been synthesized and...

  • Cephalosporin approved for UTIs.  // Urology Times;Mar96, Vol. 24 Issue 3, p46 

    Reports that the Food and Drug Administration has approved cefepime, a cephalosporin manufactured by Bristol-Myers Squibb for the treatment of uncomplicated and complicated urinary tract infection caused by Escherichia coli or Klebsiella pneumoniae.

  • Surgery And Cephalosporins: A Marriage Made In Heaven Or Time For Divorce? Morgan, Michael // Internet Journal of Surgery;2006, Vol. 8 Issue 1, p7 

    For many years now, surgeons have used cefuroxime and metronidazole for both prophylaxis and treatment of infections. Times and microbes have changed since the introduction of the cefuroxime in 1978. Cephalosporins are ineffective against the common pathogens causing surgical site infection...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics